These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 28028938)

  • 1. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
    Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
    ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.
    Ravera M; Gabano E; Zanellato I; Fregonese F; Pelosi G; Platts JA; Osella D
    Dalton Trans; 2016 Mar; 45(12):5300-9. PubMed ID: 26903367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.
    Gandin V; Marzano C; Pelosi G; Ravera M; Gabano E; Osella D
    ChemMedChem; 2014 Jun; 9(6):1299-305. PubMed ID: 24715720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation.
    Chin CF; Tian Q; Setyawati MI; Fang W; Tan ES; Leong DT; Ang WH
    J Med Chem; 2012 Sep; 55(17):7571-82. PubMed ID: 22876932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
    Ma L; Ma R; Wang Z; Yiu SM; Zhu G
    Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
    Wong DY; Yeo CH; Ang WH
    Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-Specific, Intracellular, Reductive Activation of Anticancer Pt
    Reshetnikov V; Daum S; Mokhir A
    Chemistry; 2017 Apr; 23(24):5678-5681. PubMed ID: 28319647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
    Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
    Zanellato I; Bonarrigo I; Colangelo D; Gabano E; Ravera M; Alessio M; Osella D
    J Inorg Biochem; 2014 Nov; 140():219-27. PubMed ID: 25171667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced cancer cell killing of a Pt(IV) prodrug promoted by outer-sphere coordination with polyethyleneimines.
    Garaikoetxea Arguinzoniz A; Gómez Blanco N; Ansorena Legarra P; Mareque-Rivas JC
    Dalton Trans; 2015 Apr; 44(16):7135-8. PubMed ID: 25812853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What do we know about the reduction of Pt(IV) pro-drugs?
    Wexselblatt E; Gibson D
    J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
    Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
    Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
    Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
    Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Xu Z; Wang Z; Yiu SM; Zhu G
    Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
    Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
    Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
    Deng Z; Zhu G
    Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(IV) anticancer prodrugs.
    Yao H; Gunawan YF; Liu G; Tse MK; Zhu G
    Dalton Trans; 2021 Oct; 50(39):13737-13747. PubMed ID: 34519297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
    Lee VEY; Chin CF; Ang WH
    Dalton Trans; 2019 Jun; 48(21):7388-7393. PubMed ID: 30957798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z; Deng Z; Zhu G
    Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
    Thiabaud G; McCall R; He G; Arambula JF; Siddik ZH; Sessler JL
    Angew Chem Int Ed Engl; 2016 Oct; 55(41):12626-31. PubMed ID: 27377046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.